澳大利亚52岁患者Mona Thind在2024年底度假期间接受胃肠扫描检查时被诊断为胰腺癌1。这一发现终结了数月来未被检出的情况1。随后她接受了6轮化疗和主要手术治疗1，经过15个月的治疗后战胜病魔1。
Thind的病例凸显了胰腺癌诊断的严峻挑战。来自Garvan医学研究所的Dr Amelia Parker指出，早期胰腺癌症状模糊且难以诊断1。胰腺癌是澳大利亚第八常见的癌症诊断1，约1/70的人在85岁前会被诊断为该病1，而五年存活率不足13%1。
美国食品药品监督管理局在8月批准了新的口服药物daraxonrasib（商品名Rasonque），用于既往治疗过的转移性胰腺癌1，为患者带来新的治疗希望。澳大利亚癌症研究基金会首席执行官Kerry Strydom强调，资金对推进治疗突破至关重要1。
Mona Thind, a 52-year-old Australian, received a pancreatic cancer diagnosis when undergoing a gastrointestinal scan while on holiday in late 2024.1 The discovery marked a turning point for a condition that had remained undetected despite months of prior symptoms.1 Following her diagnosis, Thind underwent six rounds of chemotherapy and major surgery to treat the disease.1
Her case highlights the diagnostic challenges associated with pancreatic cancer, which remains one of Australia's most lethal malignancies.1 According to Dr Amelia Parker from the Garvan Institute of Medical Research, early-stage pancreatic cancer presents with vague symptoms that are difficult to diagnose.1 The disease carries a grim prognosis, with fewer than 13 percent of patients surviving five years after diagnosis.1 In Australia, approximately one in 70 people will be diagnosed with pancreatic cancer before age 85, making it the eighth most common cancer diagnosis in the country.1
Recent developments offer some hope for patients with advanced disease. The U.S. Food and Drug Administration approved the oral medication daraxonrasib (brand name Rasonque) in August for patients with previously treated metastatic pancreatic cancer.1 Kerry Strydom, chief executive officer of the Australian Cancer Research Foundation, emphasized that adequate funding is essential for advancing breakthrough treatments in this field.1
评论
还没有评论，欢迎留下第一条。